Mydecine Innovations Group Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYCO.NE research report →
Companywww.mydecine.com
Mydecine Innovations Group Inc. , a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services.
- CEO
- David Joshua Bartch
- IPO
- 2014
- Employees
- 3
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $21.42M
- P/E
- 9.80
- P/S
- 0.00
- P/B
- -1.42
- EV/EBITDA
- 13.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -14.60%
- ROIC
- 47.11%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,152,136 · 84.95%
- EPS
- $-0.05 · 92.22%
- Op Income
- $-2,485,069
- FCF YoY
- -785.01%
Performance & Tape
- 52W High
- $0.35
- 52W Low
- $0.35
- 50D MA
- $0.15
- 200D MA
- $0.15
- Beta
- 2.29
- Avg Volume
- 22.95K
Get TickerSpark's AI analysis on MYCO.NE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MYCO.NE Coverage
We haven't published any research on MYCO.NE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MYCO.NE Report →